Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
dry eye disease
Biotech
Palatin plans phase 3 tweaks after dry eye study misses primary
Palatin has some changes to make for the upcoming trials of the dry eye disease drug PL9643 after the phase 3 MELODY-1 study failed on the main goal.
Annalee Armstrong
Feb 28, 2024 10:25am
Alcon’s $770M Aerie takeover delivers phase 3 dry eye wins
Jan 10, 2024 5:40am
With FDA rejection for eye drug, Aldeyra plans speedy new trial
Nov 28, 2023 4:30am
Aldeyra forewarns potential FDA rejection for dry eye med
Oct 16, 2023 2:49pm
Researchers set sights on probiotic for dry eye disease
Jun 20, 2023 11:00am
Aldeyra's dry eye disease drug scores phase 3 conjunctivitis win
Jun 15, 2023 9:30am